ADMA BIOLOGICS, INC. Repayments of Subordinated Debt
ADMA BIOLOGICS, INC. (ADMA) had Repayments of Subordinated Debt of $14.00 million as of 2020-12-08, per its 10-K filed 2022-03-24.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfSubordinatedDebt · last filed 2022-03-24
- 2020-12-08: Repayments of Subordinated Debt $14.00M.
| Period end | Repayments of Subordinated Debt |
|---|---|
| 2020-12-08 | $14.00M 10-K · filed 2022-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |